This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ekmekcioglu, S. Articles by Grimm, E. A. Search for Related Content PubMed PubMed Citation Articles by Ekmekcioglu, S. Articles by Grimm, E. A.

Inducible Nitric Oxide Synthase and Nitrotyrosine in Human Metastatic Melanoma Tumors Correlate with Poor Survival¹

Departments of Molecular and Cellular Oncology [S. E., J. E., C. M. S., E. A. G.], Pathology and Medicine (Dermatology) [V. G. P.], Biostatistics [M. M.], University of Texas, M. D. Anderson Cancer Center, Houston, Texas 77030, and Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, Brazil 01308-050 [A. C. B.]

Despite recognition of the malignant potential of human melanomas, the mechanisms responsible for the pathobiological characteristics contributing to tumor growth, vascular invasiveness, and distant organ metastasis remain undefined. Recent studies have shown that various human tumors express an inducible form of nitric oxide synthase (iNOS) and nitrotyrosine (NT), which suggests a mechanistic role of tumor-associated nitric oxide (NO) in tumorigenesis. We investigated iNOS and NT expression by immunohistochemistry in 20 human metastatic melanoma tissue specimens specifically with respect to iNOS-expressing cell types in the tumor area, pathological and clinical response to systemic therapy, potential role as a prognostic indicator, and NT formation. Our results showed that melanoma cells from 12 of 20 tumors express iNOS, yet the expression of this molecule in the tumor did not correlate with pathological or clinical response to therapy. More importantly, iNOS and NT expression by the melanoma cells strongly correlated with poor survival in patients with stage 3 disease (P < 0.001 and P = 0.020, respectively), suggesting a pathway whereby iNOS might contribute to enhanced tumor progression. In conclusion, our findings strongly suggest that iNOS expression has potential to be considered as a prognostic factor and NO as a critical mediator of an aggressive tumor phenotype in human metastatic melanomas.

This article has been cited by other articles:

				B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474. [Abstract] [Full Text] [PDF]

				Z. Yang, S. Yang, B. J. Misner, R. Chiu, F. Liu, and F. L. Meyskens Jr. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol Mol. Cancer Ther., December 1, 2008; 7(12): 3751 - 3760. [Abstract] [Full Text] [PDF]

				C.-S. Lai, S. Li, C.-Y. Chai, C.-Y. Lo, S. Dushenkov, C.-T. Ho, M.-H. Pan, and Y.-J. Wang Anti-inflammatory and antitumor promotional effects of a novel urinary metabolite, 3',4'-didemethylnobiletin, derived from nobiletin Carcinogenesis, December 1, 2008; 29(12): 2415 - 2424. [Abstract] [Full Text] [PDF]

				L. L. Hardy, D. A. Wick, and J. R. Webb Conversion of Tyrosine to the Inflammation-Associated Analog 3'-Nitrotyrosine at Either TCR- or MHC-Contact Positions Can Profoundly Affect Recognition of the MHC Class I-Restricted Epitope of Lymphocytic Choriomeningitis Virus Glycoprotein 33 by CD8 T Cells J. Immunol., May 1, 2008; 180(9): 5956 - 5962. [Abstract] [Full Text] [PDF]

				S. V. Madhunapantula, D. Desai, A. Sharma, S. J. Huh, S. Amin, and G. P. Robertson PBISe, a novel selenium-containing drug for the treatment of malignant melanoma Mol. Cancer Ther., May 1, 2008; 7(5): 1297 - 1308. [Abstract] [Full Text] [PDF]

				S. Nagaraj and D. I. Gabrilovich Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells Cancer Res., April 15, 2008; 68(8): 2561 - 2563. [Abstract] [Full Text] [PDF]

				D. D. Thomas, L. A. Ridnour, M. G. Espey, S. Donzelli, S. Ambs, S. P. Hussain, C. C. Harris, W. DeGraff, D. D. Roberts, J. B. Mitchell, et al. Superoxide Fluxes Limit Nitric Oxide-induced Signaling J. Biol. Chem., September 8, 2006; 281(36): 25984 - 25993. [Abstract] [Full Text] [PDF]

				Z. Su, J. Kuball, A.-P. Barreiros, D. Gottfried, E. A. Ferreira, M. Theobald, P. R. Galle, D. Strand, and S. Strand Nitric Oxide Promotes Resistance to Tumor Suppression by CTLs J. Immunol., April 1, 2006; 176(7): 3923 - 3930. [Abstract] [Full Text] [PDF]

				C.-H. Tang and E. A. Grimm Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines J. Biol. Chem., January 2, 2004; 279(1): 288 - 298. [Abstract] [Full Text] [PDF]

				J. A. Crowell, V. E. Steele, C. C. Sigman, and J. R. Fay Is Inducible Nitric Oxide Synthase a Target for Chemoprevention? Mol. Cancer Ther., August 1, 2003; 2(8): 815 - 823. [Abstract] [Full Text] [PDF]

				S. Ekmekcioglu, J. A. Ellerhorst, J. B. Mumm, M. Zheng, L. Broemeling, V. G. Prieto, A. L. Stewart, A. M. Mhashilkar, S. Chada, and E. A. Grimm Negative Association of Melanoma Differentiation-associated Gene (mda-7) and Inducible Nitric Oxide Synthase (iNOS) in Human Melanoma: MDA-7 Regulates iNOS Expression in Melanoma Cells Mol. Cancer Ther., January 1, 2003; 2(1): 9 - 17. [Abstract] [Full Text] [PDF]

				D. D. Thomas, M. G. Espey, M. P. Vitek, K. M. Miranda, and D. A. Wink Protein nitration is mediated by heme and free metals through Fenton-type chemistry: An alternative to the NO/O2- reaction PNAS, October 1, 2002; 99(20): 12691 - 12696. [Abstract] [Full Text] [PDF]

				M. Ikeguchi, T. Ueta, Y. Yamane, Y. Hirooka, and N. Kaibara Inducible Nitric Oxide Synthase and Survivin Messenger RNA Expression in Hepatocellular Carcinoma Clin. Cancer Res., October 1, 2002; 8(10): 3131 - 3136. [Abstract] [Full Text] [PDF]

				A.-M. Simeone, S. Ekmekcioglu, L. D. Broemeling, E. A. Grimm, and A. M. Tari A Novel Mechanism by Which N-(4-hydroxyphenyl)retinamide Inhibits Breast Cancer Cell Growth: The Production of Nitric Oxide Mol. Cancer Ther., October 1, 2002; 1(12): 1009 - 1017. [Abstract] [Full Text] [PDF]

				J. Paulukat, M. Bosmann, M. Nold, S. Garkisch, H. Kampfer, S. Frank, J. Raedle, S. Zeuzem, J. Pfeilschifter, and H. Muhl Expression and Release of IL-18 Binding Protein in Response to IFN-{gamma} J. Immunol., December 15, 2001; 167(12): 7038 - 7043. [Abstract] [Full Text] [PDF]

				A. S. Haqqani, J. F. Kelly, and H. C. Birnboim Selective Nitration of Histone Tyrosine Residues in Vivo in Mutatect Tumors J. Biol. Chem., January 25, 2002; 277(5): 3614 - 3621. [Abstract] [Full Text] [PDF]